News

Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.

Apalutamide plus androgen deprivation therapy (ADT) yielded a progression-free survival of 24.5 months vs 21.0 months with ADT alone.

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.

Heather Niccum Haag, BSN, RN, CCRN, shares her experience creating an educational resource for her patients with Von-Hippel Lindau tumors who are receiving belzutifan.

A database analysis showed that zoledronic acid led to a 64% reduction in fracture risk among patients with metastatic hormone-sensitive prostate cancer.

Nivolumab bested placebo in improving disease-free survival rates in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

Most patients experienced at least a 50% reduction in incontinence episodes at 6 months with the miniature device.

Cemiplimab has received full approval for patients with metastatic basal cell carcinoma. The most common adverse events include fatigue, musculoskeletal pain, rash, diarrhea, and anemia.

Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Phase 2a trial data suggest that single-dose URO-902 may be an effective, and safe, treatment for women experiencing difficulties with bladder control.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, discusses the importance of including frontline nurses in nursing leadership task forces.

The addition of toripalimab to perioperative chemotherapy led to a statistically significant improvement in event-free survival for patients with non–small cell lung cancer.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

The Splashblocker was found to be an effective way to reduce contaminated particles. Plastic backed pads had mixed reviews.

Radioligand therapy with 177Lu-PSMA-I&T elicited favorable PSA responses and a safety profile similar to PSMA-617.

Kathleen Gander DNP, APRN, CNS; and Sarah Middlekauff, MSN, RN, OCN, relay their experiences in implementing a hepatic artery infusion pump educational intervention for oncology nurses.

Findings from a real-world, retrospective analysis support the use of apalutamide for the prostate-specific antigen reduction among patients with metastatic castration-sensitive prostate cancer.

Oncology nurse investigators from Dana-Farber discuss the value of weighted blankets in reducing patient anxiety during infusions.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.

Acknowledging and addressing maladaptive coping mechanisms may help reduce moral distress and burnout among oncology nurses.

Elizabeth R. Cullen, MSN, ARNP, highlights the efficacy of avasopasem manganese in mitigating severe oral mucositis in patients with locally advanced head and neck cancer.

Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.

Julie C. Martin DNP, AOCN, FNP-BC, discusses best practices to approaching conversations on clinically actionable genomic results with patients.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.